LifeVantage (NASDAQ:LFVN) Updates FY 2024 Earnings Guidance

LifeVantage (NASDAQ:LFVN) updated its FY 2024 earnings guidance on Friday. The company provided EPS guidance of 0.570-0.670 for the period, compared to the consensus EPS estimate of 0.600. The company issued revenue guidance of $202.0 million-$205.0 million, compared to the consensus revenue estimate of $209.3 million.

LifeVantage Trading Up 6.2 %

Shares of LifeVantage stock opened at $6.98 on Monday. LifeVantage has a 12 month low of $3.72 and a 12 month high of $8.69. The company has a market capitalization of $88.65 million, a PE ratio of 23.46 and a beta of 0.80. The stock’s fifty day simple moving average is $6.51 and its 200 day simple moving average is $6.37.

LifeVantage Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 14th. Investors of record on Friday, May 31st will be given a $0.04 dividend. The ex-dividend date is Friday, May 31st. This is a positive change from LifeVantage’s previous quarterly dividend of $0.04. This represents a $0.16 annualized dividend and a dividend yield of 2.29%. LifeVantage’s payout ratio is currently 50.00%.

About LifeVantage

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix.